{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:38:32Z","timestamp":1790393912602,"version":"4.1.0"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CN"],"published-print":{"date-parts":[[2026,3,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>The \u03b17 nicotinic acetylcholine receptor (\u03b17nAChR), a transmitter-gated ion\nchannel, is normally activated by the endogenous neurotransmitter acetylcholine (ACh). Its activation\ntriggers a distinctive cholinergic anti-inflammatory pathway, leading to anti-inflammatory effects in\nthe central nervous system (CNS). This unique pharmacological property has positioned \u03b17nAChR as\na promising therapeutic target for multiple CNS disorders. This review delineates \u03b17nAChR\u2019s multifaceted\nroles in CNS pathophysiology, appraises current clinical trial progress of its modulators, and\nelucidates key challenges and future directions for the development of next-generation therapeutics\ntargeting \u03b17nAChR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Studies demonstrate that activation of \u03b17nAChR represents a promising therapeutic strategy for\ndiverse CNS disorders, including neurodegenerative, cerebrovascular, and neurodevelopmental diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Studies demonstrate that activation of the \u03b17nAChR is a promising therapeutic strategy for diverse\nCNS diseases, including neurodegenerative, cerebrovascular, and neurodevelopmental diseases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>This review highlights the core therapeutic value of \u03b17nAChR in CNS disorders while\nidentifying bottlenecks in its research and development. On one hand, preclinical studies show that\n\u03b17nAChR\u2019s anti-inflammatory and neuroprotective effects support its potential as a therapeutic target.\nOn the other hand, clinical trial data\u2014including limited efficacy and dose-limiting cardiovascular\nadverse effects\u2014reveal a persistent translational gap from preclinical to clinical.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although \u03b17nAChR agonists hold considerable therapeutic potential, substantial challenges\nremain in clinical translation. Major hurdles include: (1) the inherent complexity of the CNS\nmicroenvironment, which affects receptor pharmacology; (2) insufficient subtype selectivity, leading\nto off-target effects; and (3) a scarcity of clinically efficacious compounds. Addressing these limitations\nis crucial for the successful development of \u03b17nAChR-targeted therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/011570159x407773251126051902","type":"journal-article","created":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:39:49Z","timestamp":1772786389000},"update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["\u03b17 Nicotinic Acetylcholine Receptor as a Therapeutic Target in Central Nervous System Diseases: Prospects and Limitations"],"prefix":"10.2174","volume":"24","author":[{"given":"Zhe-Qi","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Xin","family":"Xu","sequence":"additional","affiliation":[{"name":"Department ofNeurology, Shanghai Changzheng Hospital, Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu-Qing","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Lv","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Li","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Die","family":"He","sequence":"additional","affiliation":[{"name":"Clinical Research Institute,Third Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nutrition, Third AffiliatedHospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei-Lei","family":"Bao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Third Affiliated Hospital of Naval Medical University, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","container-title":["Current Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/011570159X407773251126051902","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/250407\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/011570159X407773251126051902","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:39:54Z","timestamp":1772786394000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/250407\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":0,"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/011570159x407773251126051902","relation":{},"ISSN":["1570-159X"],"issn-type":[{"value":"1570-159X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-05-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}